Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...

It affects about 2% of the population and is mediated ... Alarming Rise in Rates of Advanced Prostate Cancer in California Feb. 3, 2025 — The incidence of advanced prostate cancer in California ...

The study suggests ... Inherited Gene Elevates Prostate Cancer Risk in Affected Families Jan. 28, 2025 — The inherited mutated gene WNT9B, which functions normally in embryonic prostate ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

There’s this strategy in business called the decoy effect, where marketers price things differently to manipulate customers.

Prostate cancer is a type of malignancy that arises in the prostate gland. Prostate cancer tends to develop in older men, aged 50 and over. In many cases prostate cancer develops slowly ...

The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...